“The next new $1trn stock will be…”

There are a very select few stocks that have seen their market cap exceed $1trn. And those that bought shares before that milestone will be very happy.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The flag of the United States of America flying in front of the Capitol building

Image source: Getty Images

Since The Motley Fool’s mission statement is to make the world smarter, happier and richer, we asked some of our freelance writers which US stocks they think might be next to crack the $1trn threshold — potentially making shareholders very happy indeed!

Berkshire Hathaway

What it does: Warren Buffett’s diversified holding company uses an insurance float model to invest in dozens of businesses.

By Charlie CarmanBerkshire Hathaway (NYSE:BRK.A) (NYSE:BRK.B) has broken the $700bn market capitalisation barrier, but it’s never reached the trillion-dollar threshold. I think that’s only a matter of time. As I write, the company would need to deliver a 36% share price gain to achieve this landmark.

From 1965 to 2022, Berkshire Class A stock achieved a 19.8% compound annual growth rate. Returns have slowed since the turn of the millennium, but the annual average remains firmly in double digits.

Recent results have been encouraging. In the first quarter, Berkshire posted a $35.5bn profit and accelerated its share repurchases, buying back $4.4bn of its own stock.

A major risk facing the company is the potential loss of investor confidence that could result from its CEO’s looming departure. After all, Buffett is 92.

However, his successor Greg Abel has already taken on many responsibilities, suggesting the handover could be less problematic than some fear.

Charlie Carman owns shares in Berkshire Hathaway. 

Berkshire Hathaway

What it does: Berkshire Hathaway is a diversified conglomerate that operates in sectors including insurance and retail and owns a stock portfolio.

By Christopher Ruane. The famed investor Warren Buffett has built Berkshire Hathaway over the course of decades.

Since taking the company over in 1965, Buffett has achieved a compounded annual gain of 19.8% in its per-share market value.

Some years are markedly better than others. In general, I think the defensive nature of many Berkshire businesses means that it can do well when the wider market stumbles. In 2007, for example, its compounded annual gain was 28.7% while the benchmark S&P 500 only achieved 5.5%.

The economy looks weak again to me, but one big difference is Berkshire’s massive position in Apple. If tech stocks including Apple fall, that could hurt Berkshire’s share price.

But I think the company’s broadly defensive asset base and Buffett’s steady hand on the tiller could help Berkshire ride out the next storm well. Its shares have risen 81% in five years and today the market capitalisation is $736bn.  

Christopher Ruane does not own shares in any of the companies mentioned.

Eli Lilly

What it does: Eli Lilly is a global healthcare company with products spanning oncology, immunology, diabetes and neurology.

By Ben McPoland. I think biopharma giant Eli Lilly (NYSE: LLY) could become the newest $1trn stock. Its market cap of $435bn already makes it one of the largest companies in the world.

The firm has a packed late-stage pipeline of potential blockbusters. One is its Alzheimer’s treatment, donanemab,which has successfully slowed memory and thinking decline in a rigorous phase 3 trial.

A second is Mounjaro, which is a medicine already used by people with type 2 diabetes. It is currently being assessed by US regulators and the NHS as a repositioned treatment for weight loss.

Needless to say, a proven and safe treatment for obesity (which is a global health issue) could be a huge deal for the company. Indeed, some analysts think it could become the biggest selling drug ever. And it could be approved by the end of this year. 

One risk is that this huge potential is already priced into the stock, with its trailing P/E of 72. Any disappointing regulatory news could hit the share price hard.  

Ben McPoland does not own shares in Eli Lilly.

The Motley Fool UK has recommended Apple. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Asian man looking concerned while studying paperwork at his desk in an office
Investing Articles

A stock market crash feels like it might be imminent

Conflict in the Middle East means a stock market crash feels like a real possibility right now. But being ready…

Read more »

Rolls-Royce's Pearl 10X engine series
Investing Articles

Should I buy Rolls-Royce shares as they march ever higher?

Rolls-Royce is making billions of pounds a year and looks set to do even better in future -- so what's…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

£1,000 buys 110 shares in this UK beverage stock that’s smashing Diageo 

Shares of Tanqueray-maker Diageo are languishing at multi-year lows. So why is the stock behind this tonic water brand on…

Read more »

UK financial background: share prices and stock graph overlaid on an image of the Union Jack
Investing Articles

What next for Aviva shares after a cracking set of 2025 results?

Aviva achieving its 2026 financial goals a year ahead of schedule has got to be good for the shares... oh,…

Read more »

This way, That way, The other way - pointing in different directions
Investing Articles

Should I buy stocks or look to conserve cash right now?

In a market dealing with AI uncertainty and conflict in the Middle East, should investors be looking for stocks to…

Read more »

Investing Articles

Here’s how many British American Tobacco shares it takes to earn a £1,000 monthly second income

Is an AI-resistant business with a 5.38% dividend yield a good choice for investors looking for a second income in…

Read more »

Black woman using smartphone at home, watching stock charts.
Investing Articles

1,001 Barclays shares bought 12 months ago are now worth…

Barclays shares have delivered excellent returns over the last year. But can the FTSE 100 bank keep outperforming? Royston Wild…

Read more »

Two business people sitting at cafe working on new project using laptop. Young businesswoman taking notes and businessman working on laptop computer.
Investing Articles

Get started on the stock market: 3 ‘safe’ shares for beginner UK investors to consider

Kicking off an investment portfolio on the stock market may seem like a scary prospect. Mark Hartley details a few…

Read more »